Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial

Heart Failure

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

PLoS One

Bitos K, Laptseva N, Haider T, Rossi VA, Nägele MP, Barthelmes J, Ruschitzka F, Sudano I, Flammer AJ

doi: 10.1371/journal.pone.0325668

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

Heart Failure

Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology

Eur J Heart Fail

Volterrani M, Halasz G, Adamopoulos S, Agostoni PG, Butler J, Coats AJS, Cohen-Solal A, Doehner W, Filippatos G, Jankowska E, Lam CSP, Lambrinou E, Lund LH, Rosano G, Metra M, Paolillo S, Perrone Filardi P, Rakisheva A, Savarese G, Seferovic P, Tocchetti CG, Piepoli M

doi: 10.1002/ejhf.3440

Heart Failure

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Circulation

Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, Kuder JF, Desai AS, Inzucchi SE, McMurray JJV, O'Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi MO, Drasnar T, Izzo JL, Sarman B, McGinty JE, Ramanathan K, Mulkay AJ, Przybylski A, Ruff CT, O'Donoghue ML, Murphy SA, Sabatine MS, Wiviott SD, DAPA ACT HF-TIMI 68 Trial Committees and Investigators

doi: 10.1161/CIRCULATIONAHA.125.076575

Heart Failure

Real-world use of guideline-directed therapy for heart failure: Insights from the Danish Heart Failure Registry

ESC Heart Fail

Schjødt I, Valentin JB, Johnsen SP, Mols RE, Egstrup K, Løgstrup BB

doi: 10.1002/ehf2.15320

Heart FailureFurther Publications

Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial

Eur J Heart Fail

Anker MS, Mahabadi AA, Totzeck M, Tewes M, Mincu R, Khan MS, Butler J, Keller U, Ahn J, Bullinger L, Modest DP, Landmesser U, Lehmann LH, Bercker S, Laufs U, Böhm M, Merkely B, Diek M, Heise T, Hellmich M, Placzek M, Friede T, Anker SD, Rassaf T

doi: 10.1002/ejhf.3799

Heart Failure

Contemporary implementation of guideline-directed medical and device therapies in heart failure: Insights from the Central/Eastern Europe Quality of Care Centres Survey

Eur J Heart Fail

Seferović PM, Polovina M, Krejči J, Merkely B, Tokmakova M, Huelssmann M, Miloradović V, Apostolović S, Srbinovska-Kostovska E, Radovanović S, Stojšić-Milosavljević A, Milovančev A, Zdravković M, Glavaš D, Preradović-Kovačević T, Goncalvesova E, Laufer-Perl M, Marković-Nikolić N, Kušljugić Z, Hudić-Dizdarević L, Gaita D, Kamzola G, Sepp R, Simić D, Ristić A, Ašanin M, Krljanac G, Otašević P, Stanisavljević D, Miličić D, Abdelhamid M, Savarese G, Central/Eastern Europe QCC Survey Young Investigators

doi: 10.1002/ejhf.70031

Heart Failure

Ventricular arrhythmias in acute heart failure. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Heart Rhythm Association (EHRA) and the Heart Failure Association (HFA) of the ESC

Eur J Heart Fail

Gorenek B, Wijnmaalen AP, Goette A, Mert GO, Porter B, Gustafsson F, Dan GA, Ector J, Stuehlinger M, Spartalis M, Gosau N, Amir O, Chioncel O

doi: 10.1002/ejhf.3645

Heart Failure

Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial

Heart

Sze S, Squire I, Kalra PR, Cleland JG, Petrie MC, Kalra PA, Ahmed F, Banerjee P, Boos CJ, Chapman C, Cowburn PJ, Dixon L, Duckett S, Lane R, Foley P, Lang NN, Lyons K, Ray R, Schiff R, Thomson EA, Robertson M, Ford I, IRONMAN Study group

doi: 10.1136/heartjnl-2024-324908

Related content

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Real-world use of guideline-directed therapy for heart failure: Insights from the Danish Heart Failure Registry

Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial

Contemporary implementation of guideline-directed medical and device therapies in heart failure: Insights from the Central/Eastern Europe Quality of Care Centres Survey

Ventricular arrhythmias in acute heart failure. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Heart Rhythm Association (EHRA) and the Heart Failure Association (HFA) of the ESC

Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial